000			02165ngm a2200469 a 4500
001			HST4347
003			UkLoHST
006			m c
007			cr|cna|||a||||
007			vz|czazum
008			170917s2017 enk|||||||||||s|||v|eng d
028	5	0	_a4347 _bHenry Stewart Talks
035			_a(UkLoHST)3565
040			_aUkLoHST _beng _cUkLoHST
100	1		_aWolf, Dieter A., _u(Sanford Burnham Prebys Medical Discovery Institute, USA) _4spk
245	1	0	_aMitochondrial inhibition as a novel therapeutic approach in drug-resistant cancer _h[electronic resource] / _cDieter A. Wolf.
260			_aLondon : _bHenry Stewart Talks, _c2017.
300			_a1 online resource (1 streaming video file (31 min.) : _bcolor, sound).
490	1		_aThe biomedical & life sciences collection, _x2056-452X
500			_aAnimated audio-visual presentation with synchronized narration.
500			_aTitle from title frames.
505	0		_aContents: Drug resistance in prostate cancer -- Role of androgen receptor in prostate cancer -- Difficulties in finding new prostate cancer drug targets -- Rational behind screening for p27 downregulators -- Potential for OXPHOS inhibitors in cancer therapy -- SMIP004: p27 downregulator and potential drug.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aAntineoplastic agents.
650		0	_aDrug resistance in cancer cells.
650		0	_aProstate _xCancer _xChemotherapy.
650		2	_aAntineoplastic Agents _xpharmacology.
650		2	_aAntineoplastic Agents _xtherapeutic use.
650		2	_aDown-Regulation _xdrug effects.
650		2	_aDrug Resistance, Neoplasm.
650		2	_aMitochondria _xdrug effects.
650		2	_aMitochondria _xmetabolism.
650		2	_aOxidative Phosphorylation _xdrug effects.
650		2	_aProstatic Neoplasms _xdrug therapy.
650		2	_aProstatic Neoplasms _xmetabolism.
650		2	_aProstatic Neoplasms _xpathology.
650		2	_aReceptors, Androgen.
650		2	_aS-Phase Kinase-Associated Proteins.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection.
856	4	0	_uhttps://hstalks.com/bs/3565/
999			_c76458 _d76458